<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00101010</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000407533</org_study_id>
    <secondary_id>MDA-CCOP-2004-0305</secondary_id>
    <secondary_id>NCI-6485</secondary_id>
    <secondary_id>2004-0305</secondary_id>
    <secondary_id>NCI-2009-00064</secondary_id>
    <secondary_id>2U10CA045809</secondary_id>
    <nct_id>NCT00101010</nct_id>
    <nct_alias>NCT00290446</nct_alias>
  </id_info>
  <brief_title>Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase II Study Of Rituximab-CHOP With Pegylated Liposomal Doxorubicin In Patients Older Than 60 Years Of Age With Untreated Aggressive B-Cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ortho Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
      help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping
      them from dividing. Giving rituximab together with combination chemotherapy may kill more
      cancer cells.

      PURPOSE: This phase II trial is studying how well giving rituximab together with combination
      chemotherapy works in treating older patients with diffuse large B-cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the clinical response rate in older patients with previously untreated
           aggressive diffuse large B-cell stage II-IV lymphoma treated with rituximab,
           cyclophosphamide, pegylated doxorubicin hydrochloride liposome (HCl), vincristine, and
           prednisone.

        -  Determine the cardiotoxicity and myelosuppression of this regimen in these patients.

      Secondary

        -  Determine disease-free survival and overall survival of patients treated with this
           regimen.

      OUTLINE: This is a multicenter study.

      Patients receive rituximab intravenous (IV), cyclophosphamide IV over 1-1½ hours, pegylated
      doxorubicin HCl liposome IV over 1 hour, and vincristine IV on day 1, and oral prednisone on
      days 1-5. Patients also receive filgrastim (G-CSF) subcutaneously (SC) once daily beginning
      on day 6 and continuing until blood counts recover OR pegfilgrastim SC once on day 6 (24
      hours after the completion of chemotherapy). Treatment repeats every 21 days for up to 8
      courses in the absence of unacceptable toxicity, disease progression, active hepatitis B
      virus infection, or hepatitis. Patients with no response OR who achieve less than a partial
      response after 4 courses are removed from the study.

      Patients are followed at 1 month, every 3 months for 1 year, every 4 months for 1 year, and
      then every 6 months thereafter.

      PROJECTED ACCRUAL: A maximum of 80 patients will be accrued for this study within 27 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease response (complete, complete unconfirmed, and partial responses) after courses 4 and 8</measure>
    <time_frame>Up to 24 weeks (8 cycles of 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac toxicity as measured by LVEF on ECHO after courses 4 and 8</measure>
    <time_frame>Up to 24 weeks (8 cycles of 21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival Rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The percentage of participants still alive after treatment. Survival information obtained 1 month after completion of treatment, then every 3 months for 1 year, every 4 months for one year and every 6 months thereafter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Up to 5 years or until disease progression</time_frame>
    <description>The percentage of participants with no disease progression for period of time after treatment. Survival assessed every 3 months for 1 year, every 4 months for 2 years, every 6 months for 3 years, and then yearly thereafter up to 5 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab - Combination Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab intravenous (IV), cyclophosphamide IV over 1-1½ hours, pegylated doxorubicin HCl liposome IV over 1 hour, and vincristine IV on day 1, and oral prednisone on days 1-5. Patients also receive filgrastim (G-CSF) subcutaneously (SC) once daily beginning on day 6 and continuing until blood counts recover OR pegfilgrastim SC once on day 6 (24 hours after the completion of chemotherapy). Treatment repeats every 21 days for up to 8 courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>5 mcg/kg, SC daily, start 24 hours after chemotherapy</description>
    <arm_group_label>Rituximab - Combination Chemotherapy</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>6 mg SC one time (24 hours after chemotherapy)</description>
    <arm_group_label>Rituximab - Combination Chemotherapy</arm_group_label>
    <other_name>Neulasta</other_name>
    <other_name>PEG-G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m^2 intravenous piggy back (IVPB) on day 1, administered 1st</description>
    <arm_group_label>Rituximab - Combination Chemotherapy</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750 mg/m^2 IVPB on day 1</description>
    <arm_group_label>Rituximab - Combination Chemotherapy</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin hydrochloride</intervention_name>
    <description>40 mg/m^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1</description>
    <arm_group_label>Rituximab - Combination Chemotherapy</arm_group_label>
    <other_name>Caelyx</other_name>
    <other_name>Doxil</other_name>
    <other_name>liposomal doxorubicin</other_name>
    <other_name>doxorubicin hydrochloride</other_name>
    <other_name>liposomal doxorubicin hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>40 mg/m^2 oral days 1 - 5.</description>
    <arm_group_label>Rituximab - Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>2 mg IV, day 1</description>
    <arm_group_label>Rituximab - Combination Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diffuse large B-cell lymphoma

               -  Stage II, III, or IV disease

               -  Previously untreated disease

          -  Measurable or evaluable disease

          -  No primary central nervous system (CNS) lymphoma or follicular B-cell lymphoma

        PATIENT CHARACTERISTICS:

        Age

          -  61 and over

        Performance status

          -  Zubrod 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count &gt; 1,000/mm^3*

          -  Platelet count &gt; 100,000/mm^3* NOTE: * Unless due to lymphoma-related hypersplenism or
             bone marrow infiltration

        Hepatic

          -  Bilirubin &lt; 2 mg/dL

          -  Hepatitis B surface antigen negative

          -  Hepatitis B core antibody negative

          -  Hepatitis C Virus antibody negative

        Renal

          -  Creatinine &lt; 2 mg/dL

        Cardiovascular

          -  left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram or ple gated
             acquisition (MUGA) scan

          -  No uncontrolled hypertension or cardiac symptoms

          -  Cardiologist consultation required for patients with stage A cardiac failure or any of
             the following known heart diseases:

               -  Diastolic dysfunction

               -  Prior coronary artery bypass graft

               -  Prior percutaneous transluminal coronary angioplasty

               -  Prior stent insertion

               -  Prior radiotherapy to the chest

          -  No myocardial infarction within the past 6 months

          -  No New York Heart Association class II-IV heart failure

          -  No uncontrolled angina

          -  No severe uncontrolled ventricular arrhythmias

          -  No clinically significant pericardial disease

          -  No acute ischemic or active conduction system abnormality by electrocardiogram (EKG)

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No psychiatric illness that would preclude study compliance or giving informed consent

          -  No other major life-threatening illness that would preclude study treatment

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Cardiovascular

        Surgery

          -  See Cardiovascular
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria A. Rodriguez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hembree Mercy Cancer Center at St. Edward Mercy Medical Center</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Grand Rapids</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kalamazoo</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research for the Ozarks</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Central New York, PC - Northeast Center</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057-4510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas M.D. Anderson CCOP Research Base</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2005</study_first_submitted>
  <study_first_submitted_qc>January 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2005</study_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

